Condition
Mucopolysaccharidosis Type IIIB
Total Trials
6
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Completed3
Unknown3
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07733856UnknownPrimary
Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)
NCT03784287Phase 2UnknownPrimary
A Treatment Extension Study of Mucopolysaccharidosis Type IIIB
NCT03227042UnknownPrimary
A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)
NCT02754076Phase 1Completed
A Treatment Study of Mucopolysaccharidosis Type IIIB
NCT02493998CompletedPrimary
A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)
NCT02037880Completed
Natural History Studies of Mucopolysaccharidosis III
Showing all 6 trials